Novel Agent Increases PFS for Patients with endocrine-resistant HR+/HER2- metastatic breast cancer
New treatment option provides hope for patients with endocrine-resistant HR+/HER2- metastatic breast cancer, who until today have had very limited treatment options.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
